INVESTORS & MEDIA

Press Releases

Date Title and Summary View
Toggle Summary Atara Biotherapeutics Announces Planned Chief Executive Officer Transition
SOUTH SAN FRANCISCO, Calif. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Isaac Ciechanover ,
View HTML
Toggle Summary Atara Biotherapeutics Exclusively Licenses Mesothelin-Targeted CAR T Immunotherapy for Solid Tumors
Initial results from ongoing Phase 1 study for mesothelin-targeted CAR T support activity and safety in patients with advanced solid tumors Atara’s next-generation CAR T collaboration with MSK to develop mesothelin-targeted CAR T using novel co-stimulatory domain and checkpoint inhibition
View HTML
Toggle Summary Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma (EBV+ LMS)
Second EBV‑associated solid tumor with encouraging responses to tab-cel ® Tab-cel ® safety appears consistent with a favorable risk profile and previous observations Results were presented today in an oral session at the European Society for Medical Oncology Immuno-Oncology Congress 2018 SOUTH SAN
View HTML
Toggle Summary Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting
Moffitt Cancer Center collaborators described next-generation chimeric antigen receptor T-cell (CAR T) technology that increases T cell persistence and decreases exhaustion Memorial Sloan Kettering collaborators presented positive Phase 2 clinical results for EBV-specific T cells in patients with
View HTML
Toggle Summary Atara Biotherapeutics Highlights Next-Generation and Off-the-Shelf, Allogeneic CAR T Technologies and Pipeline
Atara has assembled core technologies and capabilities to develop next-generation and off-the-shelf, allogeneic CAR T immunotherapies, collaborating with academic leaders as well as leveraging the Company’s world-class T cell manufacturing and research expertise with the goal of rapidly advancing
View HTML
Toggle Summary Atara Biotherapeutics to Host CAR T Breakfast Teach-In on November 29, 2018
SOUTH SAN FRANCISCO, Calif. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that the Company will
View HTML
Toggle Summary Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy
Findings reported in an article online and to be published in the December 2018 issue of the JCI Insight SOUTH SAN FRANCISCO, Calif. , Nov. 19, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel
View HTML
Toggle Summary Atara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress
SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the
View HTML
Toggle Summary Atara Biotherapeutics Announces Presentations Highlighting Robust Off-the-Shelf, Allogeneic T-Cell Immunotherapy Pipeline and Next-Generation CAR T Technologies at the 60th American Society of Hematology (ASH) Annual Meeting and European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2018
Moffitt Cancer Center collaborators to present next-generation chimeric antigen receptor T-cell (CAR T) technology that increases T cell persistence and decreases exhaustion Memorial Sloan Kettering collaborators to present new tab-cel ®  ( tabelecleucel)  Phase 2 clinical results for patients with
View HTML
Toggle Summary Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement
View HTML